abstract |
The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C 1 -C 8 alkyl, aryl-C 0-2 -alkyl, heteroaryl-C 0-2 -alkyl, C 3 -C 6 cycloalkylaryl-C 0-2 -alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and heteroaryl. X is a C 2 -C 5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH 2 ) n COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C 1 -C 5 alkyl, C 1 -C 5 alkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 3 -C 6 cycloalkyl, arylC 0 -C 4 alkyl and phenyl, or R3 and R4 are combined to form a C 3 -C 4 cycloalkyl. |